Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jazz Pharmaceuticals PLC

111.79
+0.35000.31%
Volume:73.54K
Turnover:8.28M
Market Cap:6.76B
PE:14.88
High:113.05
Open:112.93
Low:111.59
Close:111.44
Loading ...

Jazz Pharmaceuticals Plc : Deutsche Bank Initiates Coverage With Buy Rating; Price Target $152

THOMSON REUTERS
·
8 hours ago

Jazz Pharmaceuticals Appoints Renee Gala as New CEO, Succeeding Retiring Co-Founder Bruce Cozadd

Reuters
·
10 Jul

Jazz Pharmaceuticals Plc - Renee Gala to Become CEO Effective August 11, 2025

THOMSON REUTERS
·
10 Jul

Jazz Pharmaceuticals Plc - Bruce Cozadd to Retire as CEO, Remain Chairperson

THOMSON REUTERS
·
10 Jul

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

THOMSON REUTERS
·
10 Jul

Zymeworks Inc. Unveils Presentation on Advancements in Targeted Therapies for Cancer and Autoimmune Diseases

Reuters
·
08 Jul

RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
08 Jul

RBC Lowers Price Target on Jazz Pharmaceuticals to $167 From $172, Keeps Outperform Rating

MT Newswires Live
·
07 Jul

Bruce C. Cozadd, Chairman & CEO, Reports Disposal of Common Shares of Jazz Pharmaceuticals plc

Reuters
·
04 Jul

Jazz Pharmaceuticals says EC grants marketing authorization for Ziihera

TIPRANKS
·
01 Jul

Jazz Pharmaceuticals Receives European Commission Approval for Ziihera® to Treat Advanced HER2-Positive Biliary Tract Cancer

Reuters
·
01 Jul

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (Zanidatamab) for the Treatment of Advanced Her2-Positive Biliary Tract Cancer

THOMSON REUTERS
·
01 Jul

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

Reuters
·
30 Jun

Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits

Reuters
·
30 Jun

Avadel Pharmaceuticals Triumphs as D.C. Court of Appeals Upholds FDA Approval of LUMRYZ

Reuters
·
28 Jun

Raymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
11 Jun

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Truist Financial

TIPRANKS
·
11 Jun

Jazz Pharmaceuticals Price Target Maintained With a $202.00/Share by Needham

Dow Jones
·
11 Jun

Jazz Pharmaceuticals: FDA accepts sNDA for Zepzelca/ Atezolizumab combo

TIPRANKS
·
10 Jun

Jazz Pharmaceuticals' Zepzelca Combination Granted FDA Priority Review for First-Line Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer

Reuters
·
10 Jun